Login to Your Account



Trillium 'transforms' via $32M buy, Fluorinov encore enough?

By Randy Osborne
Staff Writer

Wednesday, January 27, 2016

With the takeover of Fluorinov Pharma Inc. comes a set of preclinical oncology compounds plus a fluorine-chemistry platform that "we can use to crank out new chemical entities to just about any target that seems promising," Trillium Pharmaceuticals Inc. CEO Niclas Stiernholm noted.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription